Premium
ALK EXPRESSION PLAYS DIFFERENT ROLES IN ANAPLASTIC LARGE‐CELL LYMPHOMAS AND OUTCOME OF CRIZOTINIB USE IN RELAPSED/REFRACTORY ALK+ PATIENTS IN A CHINESE POPULATION
Author(s) -
Li W.,
Huang L.,
Zhang F.,
Zeng J.,
Guo H.,
Liu S.,
Wei X.,
Liang Z.,
Chen F.,
Jiang X.,
Chen Y.,
Liu Y.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_155
Subject(s) - crizotinib , anaplastic lymphoma kinase , medicine , anaplastic large cell lymphoma , oncology , population , lymphoma , refractory (planetary science) , alk inhibitor , stage (stratigraphy) , gastroenterology , progression free survival , chemotherapy , lung cancer , paleontology , physics , environmental health , astrobiology , biology , malignant pleural effusion